Cambian Group (LON:CMBN)‘s stock had its “buy” rating restated by Liberum Capital in a report released on Wednesday. They presently have a GBX 238 ($3.29) price objective on the health services provider’s stock. Liberum Capital’s target price suggests a potential upside of 16.38% from the stock’s current price.
Separately, JPMorgan Chase & Co. increased their target price on shares of Cambian Group from GBX 139 ($1.92) to GBX 153 ($2.11) and gave the stock a “neutral” rating in a research note on Tuesday, November 28th.
CMBN stock opened at GBX 188.03 ($2.60) on Wednesday. Cambian Group has a 1 year low of GBX 138 ($1.91) and a 1 year high of GBX 237 ($3.27). The firm has a market cap of $385.90 and a price-to-earnings ratio of -1,566.92.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.thestockobserver.com/2018/03/21/liberum-capital-reaffirms-buy-rating-for-cambian-group-cmbn.html.
About Cambian Group
Cambian Group plc is a provider of specialist behavioral health services for children in the United Kingdom. The Company’s children services include specialist education services, specialist residential care services, foster care services and specialist mental health services. Its schools provide support to children with Autism, Asperger’s Syndrome, severe learning disabilities, challenging behavior and complex needs.
Receive News & Ratings for Cambian Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambian Group and related companies with MarketBeat.com's FREE daily email newsletter.